Sutro Biopharma develops antibody drug conjugates, a type of cancer treatment, for patients with solid tumors. STRO reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 13 | Citizens | Maintained | Buy | |
| Aug 13 | Wedbush | Reiterated | Buy | |
| Jun 11 | Truist Securities | Assumed coverage | Buy | |
| May 28 | Barclays | Initiated | Buy | |
| May 15 | Wedbush | Upgrade | Buy |
Seasonality
How STRO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in STRO in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether STRO is in one of them and how their past STRO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered STRO in an article yet. Here's the latest on the wider market.
About Sutro Biopharma
Sutro Biopharma develops antibody drug conjugates, or ADCs, which are cancer treatments that link antibodies to cell-killing drugs. It uses its XpressCF protein synthesis platform to make these protein therapies, mainly for cancers. Its lead candidate, STRO-004, is in clinical trials for solid tumors. The company also works with pharmaceutical and biotechnology companies in oncology through research collaborations, and it is based in South San Francisco, California.
- Headquarters
- South San Francisco, CA
- Founded
- 2003
- Website
- sutrobio.com ↗